On August 28, Revolution Medicines, Inc. declined 5.02% in regular trading, trading at $210.09/share, with turnover of $105 million. The pullback comes as investors lock in gains following the FDA's approval of the company's breakthrough pancreatic cancer drug Rasonque on August 26.

The FDA approved Rasonque (daraxonrasib) as the first broad-spectrum RAS-targeted oral therapy for metastatic pancreatic adenocarcinoma, extending median patient survival from 6.7 months to 13.2 months. The drug is priced at $39,800 for a 30-day supply, with annual costs exceeding $475,000. Multiple Wall Street firms raised price targets following the approval, with UBS lifting its target to $265, Jefferies to $270, and RBC to $251, all maintaining bullish ratings. RBC projects $249 million in US sales for the remainder of the year and expects rapid commercial adoption.

However, with the stock having already surged over 166% year-to-date and the market having broadly priced in the approval, the decline reflects a classic sell-the-news dynamic. Broader biotech sector weakness, including Moderna down 5.81% and BioNTech down 8.28%, also weighed on sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)